# A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct03950843` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03950843](<https://clinicaltrials.gov/study/NCT03950843>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03950843

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 162 participants.

## Technical summary

Registry record NCT03950843. Randomized; double masking; primary purpose treatment. Start 2019-04-23 (actual); primary completion 2021-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 162 participants (planned count; ClinicalTrials.gov record NCT03950843, source copy `cardio:ctgov-nct03950843-2019-05-15`, retrieved 2026-10-26)
- Started: 2019-04-23 (actual) (ClinicalTrials.gov record NCT03950843, source copy `cardio:ctgov-nct03950843-2019-05-15`, retrieved 2026-10-26)
- Primary completion: 2021-09 (anticipated) (ClinicalTrials.gov record NCT03950843, source copy `cardio:ctgov-nct03950843-2019-05-15`, retrieved 2026-10-26)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03950843, source copy `cardio:ctgov-nct03950843-2019-05-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03950843, source copy `cardio:ctgov-nct03950843-2019-05-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03950843-2019-05-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): CKD-825
- Intervention (Drug): Placebo oral capsule
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: 4b1590188568bdd618cea736e4a5e1a5f30d39fc610f9cdf22c792fe0ad5e3db
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
